Big Pharma Has a Case of Merger Mania

The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.